Blue Trust’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$65 Buy
+28
New +$40 ﹤0.01% 2450
2024
Q4
– Sell
-1,033
Closed -$1.42K – 2826
2024
Q3
$1.42K Sell
1,033
-3,054
-75% -$5.02K ﹤0.01% 2646
2024
Q2
$15.3K Buy
+4,087
New +$8.25K ﹤0.01% 1776
2024
Q1
– Sell
-1,766
Closed -$15K – 2572
2023
Q4
$15K Buy
+1,766
New +$14.4K ﹤0.01% 1432
2023
Q3
– Sell
-34
Closed – – 2228
2023
Q2
$0 Buy
+34
New +$413 ﹤0.01% 2386
2023
Q1
– Sell
-173
Closed -$1K – 2543
2022
Q4
$1K Buy
173
+124
+253% +$1.07K ﹤0.01% 2107
2022
Q3
$0 Hold
49
– – ﹤0.01% 2255
2022
Q2
$0 Buy
+49
New +$298 ﹤0.01% 1973

Other funds holding PACB

Blue Trust's PACB Position: Q3 2026 in Review

Blue Trust opened a new position in Pacific Biosciences (PACB) in Q3 2026: 28 shares worth $65. The stake represents ﹤0.01% of the portfolio and ranks #2450 among its holdings. This is a return to the name: Blue Trust previously reported a position in PACB as recently as Q3 2024.

Blue Trust first reported a position in PACB in Q2 2022 and has held it in 8 quarters since. The position peaked at $15.3K in Q2 2024. 149 funds tracked by Wall St. Rank hold PACB as of Q3 2026.

  • Blue Trust held 28 shares of Pacific Biosciences worth $65 as of Q3 2026.
  • Pacific Biosciences was a new Blue Trust position in Q3 2026.
  • Pacific Biosciences made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #2450 holding.
  • Blue Trust first reported a position in Pacific Biosciences in Q2 2022 and has held it in 8 quarters since.
  • Blue Trust's Pacific Biosciences position peaked at $15.3K in Q2 2024.
  • 149 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.